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Objectives. This study sought to determine whether early dis-
ease is identifiable in asymptomatic relatives of patients with
dilated cardiomyopathy (DCM) by means of noninvasive cardio-
logic assessment.
Background. DCM is diagnosed on the basis of advanced heart
failure, where cardiac dilation and impaired contractility are
recognized in the absence of a recognized etiology (World Health
Organization criteria). However, initial clinical presentation may
be with severe complications: thromboembolism, arrhythmia or
sudden death. DCM has recently been recognized to be familial,
with autosomal dominant inheritance in many cases. Familial
disease is present in 9% to 20% of patients with DCM, and the
ability to identify early disease in such people may improve
patient management and aid in the understanding of pathogene-
sis.
Method. We prospectively assessed 408 asymptomatic relatives
(mean [6SD] age 35 6 15 years, 193 men) of 110 consecutive
patients with DCM by means of history and physical examination,
two-dimensional echocardiography, 12-lead and signal-averaged
electrocardiography and metabolic exercise testing. We hypothe-
sized that signs of lesser cardiac dysfunction in such relatives
might indicate early disease.
Results. Twenty-nine percent of relatives had abnormal results
on the echocardiogram. Twenty percent (n 5 45) had left ventric-
ular enlargement (LVE), defined as LV end-diastolic diameter
(LVEDD) >2112% predicted; 6% (n 5 13) had depressed fractional
shortening (dFS), defined as FS <225%; and 3% (n 5 7) had frank
DCM, defined as LV dilation, impaired contractile performance
and LVEDD >2112% plus FS <225%. Other abnormalities of
cardiac function were identified in relatives with LVE or dFS: A
greater number with LVE had an abnormal metabolic exercise
test result than normal relatives (9% vs. 1%, p < 0.05). Relatives
with LVE and abnormal maximal oxygen consumption (VO2max)
(defined as VO2max <80% predicted) had a lower absolute
VO2max than normal relatives (30 6 8 vs. 43 6 9 ml/min per kg,
p 5 0.01). The QRS duration (at the 25-Hz filter) on the signal-
averaged electrocardiogram was prolonged in relatives with LVE
(103 6 13 ms) and dFS (102 6 12 ms) compared with that of
normal relatives (97 6 12 ms, p < 0.05). Over a mean 39-month
follow-up period, 12 relatives with LVE (27%) and none with dFS
developed symptomatic DCM (p < 0.0001). One relative with LVE
died suddenly, and another underwent heart transplantation.
Conclusions. Nearly one-third of asymptomatic relatives (29%)
have echocardiographic abnormalities, and 27% of such relatives
progress to development of overt DCM. Early identification of
such people would permit appropriate intervention that might
influence the serious complications and mortality of this disease.
(J Am Coll Cardiol 1998;31:195–201)
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Dilated cardiomyopathy (DCM) is diagnosed on the basis of
clinical features of advanced heart failure, with severe left
ventricular (LV) dilation and impaired contractile perfor-
mance, after exclusion of other known etiologic factors, ac-
cording to the criteria defined by the World Health Organiza-
tion (1). Patients may present with thromboembolism,
arrhythmia or sudden death before heart failure is manifest.
Disease is therefore advanced on presentation when other
noninvasive investigations are also abnormal: Signal-averaged
electrocardiographic (ECG) abnormalities have been shown to
indicate underlying myocardial fibrosis (2), and metabolic
exercise testing demonstrates a reduction in cardiac function
(3,4).
In a proportion of cases, DCM is now recognized as a
familial condition (5,6), with Mendelian autosomal dominant
inheritance; thus, first-degree relatives have a higher risk of
developing the disease. Such people may be identifiable by a
lesser degree of cardiac dilation and contractile impairment
than are conventionally accepted for a diagnosis of DCM.
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Currently, there are no criteria for the definition or recognition
of early disease in DCM. The ability to identify asymptomatic
people with early disease is a goal in the prevention of
complications and understanding of disease pathogenesis.
We speculated that relatives of affected patients may dis-
play clinical markers of early disease, before any symptoms are
manifest. Our aim was to prospectively characterize relatives of
patients with DCM, by means of noninvasive clinical cardio-
logic evaluation, to assess whether abnormalities were recog-
nizable and to determine the frequency of progression of such
abnormalities to DCM over time.
Methods
Patient characterization. Between November 1992 and
February 1996, 110 consecutive patients with idiopathic DCM,
as defined by World Health Organization criteria (1) (LV
diastolic diameter .2.7 cm/m2 and LV ejection fraction ,40%
or fractional shortening ,25%, with active exclusion of $50%
obstruction of one or more coronary arteries, active myocar-
ditis or any specific primary or secondary heart muscle disease
assessed by echocardiography, angiography and right ventric-
ular biopsy) were evaluated.
An extended family pedigree was constructed for each
patient, from which each relative was contacted and offered
appropriate counseling and screening for DCM. Of a total of
430 relatives contacted, 408 (mean [6SD] age 35 6 15 years,
193 male) from 89 families agreed to be screened (95%
screening rate). Of these 408, 54 (13%) were excluded from
further analysis because they were ,16 years old; and 79
(19%) were excluded because of known, long-standing hyper-
tension (blood pressure .150/90 mm Hg for .1 year) or
long-term high alcohol intake (men: .21 U/week; women:
.14 U/week [1 U 5 1 glass of table wine, 1⁄2 pint of beer, 1
measure of spirits or 1 measure of sherry]). A further 50
relatives with insufficient data (12%), primarily because of
geographic limitations such as residence outside the United
Kingdom and an inability to travel, were also excluded from
analysis, leaving 225 relatives (35 6 15 years old, 109 men)
available for analysis.
Each relative underwent assessment by medical history, full
clinical examination, 12-lead ECG, signal-averaged ECG, two-
dimensional echocardiogram and maximal symptom-limited
treadmill exercise testing with respiratory gas sampling.
Echocardiographic studies. All echocardiograms were ac-
quired by the same experienced operator who had no knowl-
edge of the patients’ clinical data by means of high quality
echocardiographic equipment (Hewlett-Packard 77020A or
Acuson 128XP/10c). Two-dimensional and M-mode echocar-
diography were performed using conventional techniques.
Measurements were taken from an M-mode long-axis left
parasternal view of LV wall thickness, ventricular cavity di-
mension in systole and diastole at the level of the mitral valve
tips and E and A wave filling velocities through the mitral
valve. From these measurements, the percent fractional short-
ening (FS) and E/A ratio were calculated according to stan-
dard techniques. All studies were reviewed for accuracy by a
second independent interpreter. Echocardiographic studies
were repeated in 20 relatives (44%) with LV enlargement
(LVE) and 16 normal relatives (10%) within 6 months of the
initial scan to provide an internal quality control for the
echocardiograms.
Using the formula of Henry et al. (7), the predicted LV
end-diastolic diameter (LVEDDc) was calculated from each
patient’s height and weight and thus body surface area (BSA):
LVEDDc ~predicted! 5 45.3 3 BSA0.3 2 0.03 3 Age 2 7.2.
The measured LVEDD was then expressed as a percent
according to the ratio
LVEDD% 5 LVEDD/LVEDDc.
LVEDD% $112% was chosen as the upper limit for normality
because this value represents 2 SD above the mean value in
Henry’s own data and was also previously confirmed by our
own review of 239 echocardiograms in normal subjects (data
not shown).
Two types of cardiac abnormalities were defined among
asymptomatic relatives: 1) LVE, where the left ventricle was
enlarged compared with that predicted according to the for-
mula of Henry et al. (7) (LVEDD% $112%) but with func-
tional capacity, as determined by percent fractional shortening,
was maintained; and 2) isolated depressed fractional shorten-
ing (dFS), where ventricular contractility was reduced (FS
,25%), but ventricular cavity dimensions were within the
predicted range. The clinical characteristics of patients in each
of these groups are shown in Table 1.
Metabolic exercise testing. Maximal symptom-limited met-
abolic exercise testing was performed using the standard Bruce
protocol with a Marquette MAX-1 treadmill and a dedicated
cart and respiratory gas sampling through a tight-fitting face
mask and an MGA 110 medical gas analyzer (Marquette
Anesthesia and Respiratory Care Corporation), Ventilation
Measurement Module VMM2 (Interface Associates), with
software by Breath by Breath Respiratory Data Collection
Systems (First Breath Inc.), according to established tech-
niques (8). Oxygen consumption was determined using a
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
DCM 5 dilated cardiomyopathy
dFS 5 depressed fractional shortening
ECG 5 electrocardiogram, electrocardiographic
FS 5 fractional shortening
LVE 5 left ventricular enlargement
LVEDD 5 left ventricular end-diastolic diameter
LVEDD% 5 left ventricular end-diastolic diameter expressed as
percent of left ventricular end-diastolic diameter
predicted from body surface area
RMS 5 root mean square
VO2max 5 peak oxygen uptake achieved on symptom-limited
treadmill exercise testing
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temperature-controlled polargraphic sensor. Age-predicted
maximal oxygen consumption (VO2max) was calculated using
standard formulas (9).
Signal-averaged ECG. Signal averaged ECGs were re-
corded from the orthogonal leads of an Arrhythmia Research
Technologies model 30050 machine, with standard software.
Two hundred fifty beats were averaged and stored for later
analysis, when all measurements and computations were made
automatically without manual intervention.
Time domain analysis was performed at high pass filter
settings of 25 and 40 Hz using a bidirectional four-pole
Butterworth filter. After amplification, averaging and filtering,
the signals were combined into a single vector magnitude (x2 1
y2 1 z2)1/2, and three conventional time domain indexes were
calculated: duration of the total QRS complex; duration of the
low amplitude (,40 mV) signals of the terminal portion of the
QRS complex; and the root mean square (RMS) voltage of the
terminal 40 ms of the QRS complex. Results were considered
abnormal when at least two of the three conventional variables
were beyond the normal range (total QRS duration .120 ms;
low amplitude [,40 mV] signals .40 ms; and RMS voltage in
the terminal 40 ms of the QRS complex ,25 mV at the 25-Hz
filter setting).
Statistical analysis. Chi-square analysis, Fisher exact test,
unpaired two-tailed Student t test or stepwise logistic regres-
sion analysis was used as appropriate. Tests were performed
using C-Stat (Cherwell Scientific, Oxford, UK) or SPSS (SPSS
Inc.) software, on an IBM PC. A value ,0.05 was considered
statistically significant. Results are expressed as mean value 6
SD.
Results
Echocardiographic studies. Of 225 relatives assessed, 7
(3%) were found to have DCM, 45 (20%) LVE and 13 (6%)
dFS; 160 (71%) were echocardiographically normal.
Relatives determined to have LVE had, in addition, signif-
icantly impaired LV function compared with normal relatives
(FS: 33 6 5% vs. 36 6 6%, p 5 0.01). Relatives determined to
have dFS only had, in addition, significant LVE compared with
normal relatives (LVEDD%: 112 6 13% vs. 102 6 7%, p ,
0.001).
Relatives with both LVE and dFS had significantly enlarged
left atria compared with normal relatives (LVE: 35 6 5 vs.
33 6 5 mm, p 5 0.001; dFS: 39 6 4 vs. 33 6 5 mm, p 5 0.04).
The measured E/A ratio in all relatives was significantly lower
than predicted values (1.55 6 0.83 vs. 1.75 6 0.44, p 5 0.03).
In subjects with LVE, the E/A ratio was significantly lower
than in normal relatives (1.29 6 0.72 vs. 1.60 6 0.71, p 5 0.04).
There was no significant change in LVEDD in subjects who
underwent repeat echocardiography within 6 months of the
initial scan for either the LVE or normal group (Table 2). This
finding indicates that an initial echocardiographic diagnosis of
LVE or normality could be confidently repeated within 6
months, suggesting that LVE in these circumstances is not an
ephemeral finding.
Clinical findings. Results of clinical examination of the
cardiovascular system were abnormal in a greater proportion
of subjects with LVE and dFS than in relatives with normal LV
function. The majority of abnormal findings were minor, and
no relative had signs of overt heart failure; there were signs of
either a third or fourth heart sound, and two subjects had
elevation of jugular venous pressure. One patient had a
pansystolic murmur.
Thirty-one percent (n 5 4) of subjects with dFS had
abnormal examination results compared with only 4.7% (n 5













Age (yr) 34.4 6 17.2 36.0 6 14.9 37.2 6 16.6 35.0 6 14.7 40.7 6 22.4
M/F 5/2 27/18 9/4 70/90 7/5
Race
White 7 44 13 151 11
Black 0 0 0 4 0
Asian 0 1 0 5 1
Data presented are mean value 6 SD or number of relatives. DCM 5 dilated
cardiomyopathy; dFS 5 depressed fractional shortening; F 5 female; LVE 5 left
ventricular enlargement; M 5 male.










Age (yr) 35 6 16 32 6 15 0.27
LA diameter (mm) 35 6 5 33 6 5 0.001*
%FS 33 6 5 36 6 6 0.01*
Total exercise time (min) 12.8 6 3.1 12.4 6 2.7 0.53
QRS 25 (ms) 103 6 13 97 6 12 0.02*
LPD 25 (ms) 29 6 11 25 6 8 0.05*
RMS 25 (mV) 57 6 37 77 6 51 0.06
QRS 40 (ms) 98.1 6 11.4 95.3 6 10.6 0.22
LPD 40 (ms) 30.4 6 10.5 26.6 6 9.5 0.06
RMS 40 (mV) 41.7 6 23.5 53.1 6 35.8 0.1
Absolute VO2max (ml/min per kg) 40 6 9.9 37 6 8.8 0.38
LVEDD (mm)
Abnormal VO2max 56.5 6 3.4 46 6 3.6 0.005*
Abnormal SAECG 56.7 6 3.6 45.5 6 6.4 0.004*
Initial echo study 55.4 6 4 48 6 4
Repeat echo study 54.9 6 4† 50.6 6 5‡
*Significant difference. †p 5 0.73, ‡p 5 0.1, initial versus follow-up left
ventricular end-diastolic diameter (LVEDD). Data presented are mean value 6
SD. echo 5 echocardiographic; LA 5 left atrial; LPD 25 5 low amplitude signal
duration at 25-Hz filter setting; LPD 40 5 low amplitude signal duration at
40-Hz filter setting; LVE 5 left ventricular enlargement; QRS 25 5 QRS
duration at 25-Hz filter setting; QRS 40 5 QRS duration at 40-Hz filter setting;
RMS 25 5 root mean square voltage at 25-Hz filter setting; RMS 40 5 root mean
square voltage at 40-Hz filter setting; SAECG 5 signal averaged electrocardio-
gram; VO2max 5 maximal oxygen consumption; %FS 5 percent fractional
shortening.
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8) of normal relatives (p , 0.0001). In relatives with LVE,
10.4% (n 5 5) had abnormal examination results (p , 0.01 vs.
normal relatives).
Exercise testing and signal-averaged electrocardiography.
There were significant metabolic exercise test abnormalities in
relatives with LVE. A greater number of relatives with LVE
had abnormal VO2max values compared with normal relatives
(4.9% vs. 2.1%, p , 0.05). In relatives with LVE and abnormal
VO2% (,80% predicted), there were significantly lower abso-
lute VO2max values than in normal relatives (30 6 7.8 vs.
42.5 6 9.1 ml/min per kg, p 5 0.01). LVEDD was smaller in
subjects with LVE and abnormal VO2max values, than in those
with normal VO2max values (45.6 6 1.9 vs. 49.4 6 2.3 mm, p 5
0.01), suggesting that the observed metabolic impairments in
LVE are not simply a function of a dilated ventricle.
In subjects with LVE, there were other abnormalities on
signal-averaged electrocardiography: QRS duration (at 25 Hz):
103 6 13 versus 97 6 12 ms, p 5 0.02; low amplitude signal
duration (at 25 Hz): 29 6 11 versus 25 6 8 ms, p 5 0.05 (Table
2). Relatives with dFS had a lower RMS voltage (at 40 Hz)
(30 6 8.9 vs. 57.6 6 39.6 mV, p 5 0.05) and a longer total QRS
duration (at 40 Hz) (101.6 6 11.7 vs. 94 6 10.4 ms, p 5 0.05)
than normal subjects (Table 3).
Follow-up data. Over a prospective follow-up period of
39 6 14 months (median 39, range 14 to 59), 12 relatives with
LVE (27%) and none with dFS developed DCM (p , 0.0001).
No relatives who were assessed initially as normal developed
DCM, but three (2%) progressed to develop LVE (Table 4).
One relative who progressed from LVE to DCM underwent
successful heart transplantation. Two relatives with LVE died
(sudden cardiac death in one with mild palpitations, and
noncardiac death in one).
Stepwise logistic regression analysis using SPSS 6.0 software
found a predictive association between LVEDD and the
likelihood of progression to DCM from LVE, but no other
single metabolic or ECG variable had predictive value (Table
5).
Familial clustering. The present study elucidated familial
clustering of people with DCM, LVE and dFS; the prevalence
of familial disease when LVE was included in the analysis was
48% (110 probands, 45 with LVE, 7 with DCM). Two main
patterns of inheritance were seen: The majority of pedigrees
studied appear to conform most closely to an autosomal
dominant pattern of inheritance, but there is also a more
sporadic pattern of transmission, with occasional generations
being phenotypically bypassed completely. It may be that this
latter case represents a form of variable penetrance. In the
remaining families, no clear other pattern of inheritance was
seen. The heterogeneity of the inheritance patterns may also
indicate polygenic transmission. Examples of pedigrees that we
observed are shown in Figure 1.
Probability assessment. Continuous probability, based on
LV size and percent FS at initial assessment, may be deter-
mined by comparing the distribution (10) of these variables in
patients with DCM at presentation versus that in people with
normal variables at initial screening. Both of these groups of
data are normally distributed, and the probability thus calcu-
lated refers to any individual measurement belonging to one or
the other distribution. We calculated these probabilities for a
range of LV diameters and similarly for a range of FS values
and show the results as the probability curves in Figure 2A.
On retrospective assessment, relatives with LVE tend to
have a higher rating on the probability curve than do normal







(n 5 160) p Value
Age (yr) 35.4 6 17.2 32.0 6 15 0.43
LA diameter 39 6 4 33 6 5 0.04*
LVEDD (mm) 50.2 6 4 48 6 4 0.09
LVEDD% 112 6 13 102 6 7 ,0.001*
Total exercise time (min) 13.9 6 1.9 12.4 6 2.7 0.38
QRS 25 (ms) 104 6 11 99 6 12 0.28
LPD 25 (ms) 24 6 8 25 6 12 0.85
RMS 25 (mV) 53.8 6 19 77 6 51 0.21
QRS 40 (ms) 101.6 6 11.7 94 6 10.4 0.05*
LPD 40 (ms) 30.5 6 6.8 26.1 6 9 0.26
RMS 40 (mV) 30 6 8.9 57.6 6 39.6 0.05*
Absolute VO2max (ml/min per kg) 42.9 6 7.7 38.1 6 8.9 0.31
*Significant difference. Data presented are mean value 6 SD. Abbreviations
as in Tables 1 and 2.
Table 4. Progression of Disease During Follow-Up Period of 39 6
14 Months
Initial Assessment Follow-Up Assessment
Group No. (%) Progression to No. (M/F) Age (yr)
DCM 7 (3%) N/A
LVE 45 (20%) DCM 12 (7/5) 40.7 6 22.4
dFS 13 (6%) LVE or DCM 0
Normal 160 (71%) LVE 3 (1/2) 22.7 6 5.9
Data presented are mean value 6 SD or number (%) of relatives. Abbrevi-
ations as in Tables 1 to 3.
Table 5. Logistic Regression: Relation Between Progression of Left






LPD 25 20.21 0.21
QRS 25 0.19 0.46
RMS 25 0.003 0.92
LPD 40 0.03 0.74
QRS 40 20.15 0.60
RMS 40 20.01 0.90
Abbreviations as in Table 1.
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relatives. An obvious limitation of this type of analysis is that
the two observed echocardiographic dimensions may be abnor-
mal for many reasons other than DCM; for example, ischemic
cardiac enlargement would result also in a high probability
score on our curve. Therefore, these curves are a guide only for
patients in whom other causes of LVE can be excluded.
Combining the individual probabilities shown in Figure 2A
allows more accurate assessment of individual probability; the
combination curves are shown in Figure 2B.
Discussion
Few data and no definitions exist to identify early disease in
familial DCM. In the present study, asymptomatic echocardio-
graphic abnormalities were seen in 29% of relatives. The most
common abnormality was LVE. The association of other
abnormalities (clinical, metabolic and ECG) with LVE sug-
gests that it is not simply a “variant” of normality or a
manifestation of high physical fitness, as in the athletic heart
syndrome. The present study also demonstrates that a propor-
tion (27%) of relatives with LVE progress to symptomatic
DCM; it is therefore likely that LVE itself represents an early
stage in the disease process.
Depressed FS does not appear to share the same risk of
progression to DCM; it may thus represent a limited manifes-
tation rather than early disease.
The present study determined that abnormalities of cardiac
function are identifiable in asymptomatic relatives. Although
not fulfilling conventional criteria for the diagnosis of DCM,
the abnormalities in a subset of these people progress to the
extent that conventional diagnostic criteria are achieved, and
symptoms appear that lead to a number of disease complica-
tions, including sudden death.
It is therefore suggested that the assessment of risk in any
individual relative must be based on the noninvasive investi-
gations outlined in the present study. Echocardiography re-
mains the most important of these investigations because
LVEDD in LVE has a statistically significant predictive asso-
ciation with the development of DCM. The lack of symptoms
in subjects with LVE does not necessarily indicate a good
prognosis. Abnormalities on physical examination of the car-
diovascular system are more frequent in relatives with LVE
than in normal relatives; hence, although not specific, such
abnormal signs on physical examination must be carefully
sought.
Abnormalities on standard and high resolution electrocar-
diography or abnormal oxygen consumption on exercise testing
does not have the predictive value of increased LVEDD on
echocardiography. Nevertheless, these abnormalities are more
common in relatives with LVE and should be assessed if
facilities are available because the finding of such abnormali-
ties will augment the individual likelihood of any person with
LVE being at risk for disease progression.
Analysis of the combined probability curves (Fig. 2B) may
Figure 1. Typical pedigrees in
relatives with DCM, LVE and
dFS. Top pedigree, Family A;
bottom pedigree, Family B.
199JACC Vol. 31, No. 1 BAIG ET AL.
January 1998;195–201 EARLY DISEASE IN DILATED CARDIOMYOPATHY
be used as a guide to individual risk in a relative with LVE.
However, assessment of these curves suggests that our current
definition of the upper limit for normal LV size (,112% of
that predicted according to the formula of Henry et al. [7]) is
considerably underestimated in the context of DCM. For
future analyses, it appears that an upper cutoff of 118% would
allow more frequent identification of at-risk subjects because
this value infers a chance of ;50% that a relative with LVE
will develop DCM in the presence of FS of 25% (Fig. 2B).
Whether subjects with LVE or dFS require therapeutic
intervention remains to be determined because no specific
treatment data exist for these groups. Data from the asymp-
tomatic limbs of the Studies of Left Ventricular Dysfunction
(SOLVD) (11) and Survival and Ventricular Enlargement
(SAVE) (12) trials suggest that angiotensin-converting enzyme
(ACE) inhibition is beneficial in people with asymptomatic LV
dysfunction, and it is reasonable to assume that such benefits
will extend to relatives with LVE. However, whether such
treatment with ACE inhibition will alter the risk of disease
progression remains unknown and is currently the subject of
further study. Furthermore, if myocardial inflammation in the
context of early disease can be conclusively proved, then
intervention with immunosuppression or perhaps cytokine
antagonists may become an appropriate additional therapy.
The identification of relatives with early DCM is important
in establishing the true prevalence of familial disease; if the
premise that a proportion of relatives with LVE will eventually
develop DCM is correct, then current figures for the preva-
lence of familial disease (9% to 20%), and therefore for
offspring risk, are considerably underestimated. This underes-
timation is supported by the findings of the present study,
which showed that when LVE is included as evidence of early
disease, the prevalence of familial disease rises to 48%.
Conclusions. Twenty-six percent of relatives of patients
with DCM have asymptomatic LV enlargement or isolated
dFS demonstrable on echocardiography. Other noninvasive
investigation results are also abnormal in these subgroups.
Prospective follow-up revealed that 27% of such initially
asymptomatic subjects with LVE go on to develop DCM and
may suffer the recognized complications of the condition.
We gratefully acknowledge the assistance of Karen Reardon, computer databas-
ing; Vicky Murday, MD, Department of Medical Genetics; Sr. Carolanne Page
and Sr. Mary Gould, clinical organization; Gill Smith and Sally Nunn, Senior
Echocardiographers; and Michelle Leigh-Jones, Chief Cardiac Technician, in the
completion of this study.
References
1. Brandenburg RO, Chazov E, Cherian G, et al. Report of the WHO/ISFC
task force on definition and classification of the cardiomyopathies. Circula-
tion 1981;64:1397–9.
2. Yamada T, Fukunami M, Ohmori M, et al. New approach to the
estimation of the extent of myocardial fibrosis in patients with dilated
cardiomyopathy: use of signal-averaged electrocardiography. Am Heart J
1993;126:626 –31.
3. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopul-
monary exercise testing using percent achieved of predicted peak oxygen
Figure 2. Probability of DCM according to (A) LVEDD% and percent
FS and (B) combined LVEDD% and percent FS.
200 BAIG ET AL. JACC Vol. 31, No. 1
EARLY DISEASE IN DILATED CARDIOMYOPATHY January 1998;195–201
uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll
Cardiol 1996;27:345–52.
4. Van den Broek SA, Van Veldhuisen DA, De Graeff PA, Landsman ML,
Hillege H, Lie KI. Comparison between New York Heart Association
classification and peak oxygen consumption in the assessment of functional
status and prognosis in patients with mild to moderate chronic congestive
heart failure secondary to either ischemic or idiopathic dilated cardiomyop-
athy. Am J Cardiol 1992;70:359–63.
5. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med 1994;330:
913–9.
6. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated
cardiomyopathy in a series of patients with idiopathic dilated cardiomyopa-
thy. N Engl J Med 1992;326:77–82.
7. Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in
normal subjects from infancy to old age. Circulation 1980;62:1054–61.
8. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in
hypertrophic cardiomyopathy: a two dimensional echocardiographic study.
J Am Coll Cardiol 1983;2:437–44.
9. Blackie SP, Fairbarn MS, McElvaney GN, Morrison NJ, Wilcox PG,
Pardy RL. Prediction of maximal oxygen uptake and power during cycle
ergometry in subjects older than 55 years of age. Am Rev Respir Dis
1989;139:1424 –9.
10. Dennis NR, Carter CO. Use of overlapping normal distributions in genetic
counselling. J Med Genet 1978;15:106–8.
11. Effect of enalapril on mortality and the development of heart failure in
asymptomatic patients with reduced left ventricular ejection fractions: the
SOLVD Investigators [published erratum appears in N Engl J Med 1992;
327:1768]. N Engl J Med 1992;327:685–91.
12. Pfeffer MA, Braunwald E, Moye LA, et al., for the SAVE Investigators.
Effect of captopril on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction: results of the Survival and Ventric-
ular Enlargement trial. N Engl J Med 1992;327:669–77.
201JACC Vol. 31, No. 1 BAIG ET AL.
January 1998;195–201 EARLY DISEASE IN DILATED CARDIOMYOPATHY
